Ontology highlight
ABSTRACT:
SUBMITTER: Valeyre D
PROVIDER: S-EPMC4230393 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Valeyre Dominique D Albera Carlo C Bradford Williamson Z WZ Costabel Ulrich U King Talmadge E TE Leff Jonathan A JA Noble Paul W PW Sahn Steven A SA du Bois Roland M RM
Respirology (Carlton, Vic.) 20140518 5
<h4>Background and objective</h4>Pirfenidone is an oral antifibrotic agent that is approved in several countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a comprehensive analysis of safety across four clinical trials evaluating pirfenidone in patients with IPF.<h4>Methods</h4>All patients receiving pirfenidone 2403 mg/day in the Phase 3 CAPACITY studies (Studies 004 and 006) and all patients receiving at least one dose of pirfenidone in one of two ongoing open-label ...[more]